Trial · NCT01750190
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy | Roxadustat | Baseline | 9.10 | Standard Deviation 0.75 | g/dL |
| United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy | Placebo | Baseline | 9.09 | Standard Deviation 0.69 | g/dL |
| United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy | Roxadustat | Change at Weeks 28 to 52 | 2.00 | Standard Deviation 0.952 | g/dL |
| United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy | Placebo | Change at Weeks 28 to 52 | 0.16 | Standard Deviation 0.895 | g/dL |
| Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy | Roxadustat | 523 | Participants | ||
| Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy | Placebo | 20 | Participants | ||
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Roxadustat | Baseline | 9.09 | Standard Deviation 0.749 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Placebo | Baseline | 9.09 | Standard Deviation 0.694 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Roxadustat | Change at Weeks 28 to 36 | 2.02 | Standard Deviation 1.067 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Placebo | Change at Weeks 28 to 36 | 0.20 | Standard Deviation 0.994 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN) | Roxadustat | Baseline | 9.10 | Standard Deviation 0.750 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN) | Placebo | Baseline | 8.99 | Standard Deviation 0.668 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN) | Roxadustat | Change at Weeks 28 to 52 | 2.02 | Standard Deviation 0.933 | g/dL |
| Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN) | Placebo | Change at Weeks 28 to 52 | 0.18 | Standard Deviation 0.946 | g/dL |
| Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Roxadustat | 467 | Participants | ||
| Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | Placebo | 56 | Participants | ||
| Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28 | Roxadustat | Baseline | 97.74 | Standard Deviation 39.09 | mg/dL |
| Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28 | Placebo | Baseline | 96.39 | Standard Deviation 40.06 | mg/dL |
| Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28 | Roxadustat | Change at Weeks 12 to 28 | -18.48 | Standard Deviation 29.60 | mg/dL |
| Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28 | Placebo | Change at Weeks 12 to 28 | 0.22 | Standard Deviation 29.37 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01750190/results